Purchase Order 75N91025P00429

Award Date 7/12/25
Potential Completion Date 8/12/25
Potential Value $15K
Ultimate Awardee
Becton, Dickinson & Co
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $750,000.00 firm fixed price purchase order contract awarded by the National Cancer Institute to Becton, Dickinson & Co (BD) for a special order BD Biosciences LSRFortessa X-30 flow cytometer. The contract has no set-aside designation. BD is a manufacturer and supplier of medical devices, instruments, reagents, and related products to healthcare institutions, clinical laboratories, pharmaceutical companies, and the general public. BD has received numerous federal contract awards as...
This is a firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for maintenance and support services for a BD LSR Fortessa flow cytometry instrument and associated instrumentation. The contract has a base period from August 1, 2021 to July 31, 2024, with a ceiling value of $73,900.44. The contract was awarded competitively without a set-aside designation, indicating...
This is a $126,090.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Becton, Dickinson and Company (BD) for a service contract to provide an LSRFortessa flow cytometer with lasers. The contract does not have a set-aside designation. BD, a large medical technology and manufacturing company, will deliver the flow cytometry instrument to support research activities at the NIH...
This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for $100,792.44. The contract requires BD to provide all labor, material, and equipment necessary to maintain and perform preventive maintenance on a BD FACSymphony A3 flow cytometry analyzer and its five lasers. The award has no set-aside designation, indicating it was competed on a full and open basis. BD is a...
This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for maintenance services on two BD LSR Fortessa SORP flow cytometers. The contract has a base period of performance from April 17, 2021 through April 16, 2022, with four 12-month option periods, for a total potential value of $80,838. The contract does not have a set-aside designation. BD is a large, for-profit...
This is a $99,717.48 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to Becton, Dickinson and Company (BD). The contract is for the provision of three LSR FORTESSA flow cytometers with laser systems, as well as an annual service agreement. There is no set-aside designation for this award. BD is a major manufacturer of medical devices, instruments, and supplies, including...
This is a purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to Becton, Dickinson and Company (BD) for a Laser Scanning Robotic (LSR) FORTESSA cytometer and associated maintenance services. The $15,976.71 firm fixed-price contract has an ultimate completion date of September 30, 2025. BD Biosciences, a division of the larger BD corporation, will provide the specialized flow cytometry equipment...
This is a firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI) to Becton, Dickinson and Company (BD) for $161,406.02. The contract is for BD Biosciences, a division of BD, to provide specialized equipment, reagents, and services to support biomedical research and clinical applications through flow cytometry, cell imaging, and genomics technologies. BD is a global medical technology company that has extensive experience providing a wide range of goods and...
This federal contract award from the National Cancer Institute (NCI) to Becton, Dickinson And Company (BD) is for the procurement of a BD BIOSCIENCES - LSR II LASER and LSR/FORTESSA Z230SFF WORKSTATION BUNDLE SYSTEM. The $86,150.00 firm fixed-price purchase order has an ultimate completion date of August 5, 2015. The contract was awarded on May 6, 2015 and does not have a set-aside designation. BD Biosciences, a division of BD, is a major supplier of specialized biomedical research equipment and...
This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for maintenance services on a BD Biosciences LSRFortessa Special Order Research Product (SORP) analytical cytometer. The one-year base period contract, valued at $64,584.00, provides preventive maintenance, repairs, software updates, and technical support for this specialized flow cytometry instrument used by the NCI's...

This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for the pre-contract inspection of a BD LSRFortessa 4B/2R/2UV 3 laser flow cytometry instrument. The $15,000.00 contract does not have a set-aside designation, reflecting BD's competitive position as a large, established manufacturer of medical technologies and laboratory equipment. The LSRFortessa instrument is essential for the NCI's routine research activities, as it enables quantitative analysis of cell cycle and DNA. BD is a global medical technology company that provides a wide range of instruments, diagnostics, and related services to numerous federal agencies, including the NIH and its various institutes. This contract award suggests BD's ongoing role in supplying specialized flow cytometry systems and support to the NCI and other NIH research programs.

Generated 7/8/25, 2:36 PM